

Nacton allows the patient, not the ulcer, to dictate his diet : Mesopotamian white glazed bowl, 10th century.

Contributors

Beecham Research Laboratories

Publication/Creation

Brentford : Beecham Research Laboratories, 1964.

Persistent URL

<https://wellcomecollection.org/works/aj4dncdz>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).



Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

NACTON

allows the patient,
not the ulcer,
to dictate his diet



Mesopotamian white glazed bowl, 10th century

in the treatment
of peptic ulcer

NACTON

Results from a controlled three-year trial of NACTON showed that ulcer patients were able to eat food of their own choice without adverse effects, and that absenteeism from work was negligible.

NACTON also:

- gave prolonged freedom from pain
- reduced dependence on antacids

At optimum dosage levels (the maximum dose which does not give rise to side effects), Nacton effectively controls gastric secretion of acid and reduces gastric spasm.

Many papers now pay tribute to the very successful results obtained with Nacton in the treatment of gastric disorders.



(Reproduced by courtesy of the Victoria and Albert Museum trustee)

but where anxiety complicates
ulcer management

NACTISOL

NACTISOL combines the advantages of NACTON and butabarbital. Butabarbital provides relief from anxiety and tension.

In the treatment of peptic ulcer
NACTISOL gives the dual effect of

- adequate control of acid secretion
- mild sedation



NACTON

NACTISOL

(Nacton and Nactisol are Registered Trade Marks)

Indications

Peptic Ulcer
Hyperacidity
Stomal Ulcer

Nacton and Nactisol are of value in the management of spastic colon, ulcerative colitis, biliary dysfunction and nocturnal enuresis. Nacton has also proved useful in post-gastrectomy and colostomy patients.

Contra-indications

Nacton and Nactisol should be used only under close supervision for patients in whom tachycardia, difficulty of micturition or increase in ocular tension are undesirable.

Average Dosage

Two tablets (4 mg.) three times daily and at night. If required, the dose should be increased to meet individual requirements

Side Effects

In therapeutic doses, no side effects are caused. If these occur, they are a sign of overdosage.

Content

Each NACTON tablet contains 2 mg. poldine methyl-methosulphate. Each NACTISOL tablet contains 2 mg. NACTON with 7½ mg. butabarbital.

Availability

Canisters of 50 and 250 tablets.
The basic N.H.S. costs of an average day's treatment (8 tablets) with Nacton and Nactisol are 1s. 0d. and 1s. 1d. respectively.

References

A full list of references is available on request.
Brit. med. J., (1957), 2, 275.
Ibid (1958), 1, 1030.
Ibid (1961), 1, 1076.
Ibid (1961), 1, 1250.
Ibid (1961), 1, 1575.
Lancet (1962), 1, 1002.



NACTON and NACTISOL are products of British research at
Beecham Research Laboratories
Brentford, England. ISLeworth 4111